Herpes simplex virus-1 Glycoprotein C mutants for treating unwanted hyperproliferative cell growth
AssigneeOnyx Pharmaceuticals, Inc.
InventorsSylvie Laquerre, Terry Hermiston
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmaceutical compositions, kits, and methods of use thereof, comprising, a mutant human herpes simplex virus, which is cytopathic to susceptible target cells, such as neoplastic cells. Preferably, the virus does not produce a functionally active wild-type gC polypeptide coded for the UL44 gene.
Claims10
A method for treating a neoplasm comprising cells, comprising:
- administering to said neoplasm an amount of a mutant human herpes simplex virus which is oncolytic to cells in said neoplasm, wherein said virus does not produce a functionally active wild-type glycoprotein C polypeptide capable of binding heparan sulfate.
A kit comprising a mutant human herpes simplex virus which is oncolytic to cells in a neoplasm, wherein said virus does not produce a functionally active wild-type glycoprotein C polypeptide capable of binding heparun sulfate and a chemotheraputic agent.
Dependencies are inferred from the claim text.